Marinus Pharmaceuticals, Inc. 5 Radnor Corporate Center 100 Matsonford Rd, Suite 500 Radnor, PA 19087
Our independent auditor is Ernst & Young.
We went public on July 31, 2014.
The fiscal year ends on December 31st.
Our shares are traded on the Nasdaq Stock Market.
We do not pay dividends.
Our transfer agent is the American Stock Transfer and Trust Company.
Please contact your broker or, if you beneficially own your shares, contact our transfer agent.
We do not have a direct stock purchase plan.
Please contact a licensed stockbroker in order to purchase shares.
The next earnings release will be within 40 days of the end of our fiscal quarter.
Sasha Damouni Ellis VP, Investor Relations & Corporate Communications Marinus Pharmaceuticals, Inc. Info@Marinuspharma.com 484-253-6792(o) 484-801-4669(f)
100 Matsonford Road; Suite 500 Radnor, PA 19087
All SEC filings can be found and downloaded here: https://ir.marinuspharma.com/financials/sec-filings/default.aspx.
Our CUSIP is 56854Q200.
To be added to the distribution list, follow this link: http://marinuspharma2020ir.q4web.com/resources/investor-email-alerts/default.aspx.
You can also contact us at: Contact Us.
You can find a copy of our annual report here: https://ir.marinuspharma.com/financials/annual-reports/default.aspx.
Our annual matting is generally held virtually between late April and early June each year.